Advice from the leader of Cleveland Clinic Cancer Center
In spite of the challenges posed by the novel coronavirus pandemic, it is essential that patients with suspected, newly diagnosed or progressive cancers receive ongoing care.
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
Cleveland Clinic Cancer Center has continued to provide consultation and treatment during the pandemic, utilizing virtual visits and, when necessary, in-person clinical care with appropriate precautions.
In addition to serving patients in our own healthcare system, the cancer center has connected with oncologists in regions hard-hit by COVID-19 who have had to defer or delay cancer treatments, to offer temporary care until conditions improve and patients can resume seeing their own physicians. (Oncologists in need of this assistance should call Cleveland Clinic’s Cancer Answer Line, 866.223.8100.)
How is it possible to maintain patient services during this difficult time? The key is taking care of the cancer center’s workforce so they can care for others, says Cleveland Clinic Taussig Cancer Institute Chair Brian J. Bolwell, MD. That means addressing fears, sharing information regularly and transparently, and providing the support and encouragement people need to do their jobs.
Learn more about Dr. Bolwell’s approach to leading the cancer center and providing care during COVID-19 by reading his latest column in Oncology Times. In addition to heading Cleveland Clinic Cancer Center, Dr. Bolwell is Cleveland Clinic’s Director of Physician Leadership and Development.
Advertisement
Advertisement
Care paths and research initiatives aim to answer unmet clinical needs
Study shows high rate of hematologic responses, low rate of disease progression
Bispecific antibody bridging therapy deepens durability of BCMA CAR T-cell therapy without overlapping toxicities in patients with relapsed/refractory multiple myeloma
Phase 2 study brings pivotal advances in treatment efficacy and safety for the most challenging-to-treat population
Patient with quadruple refractory multiple myeloma achieves complete response with cell therapy
Distinct baseline immune profiles can predict response and resistance to different types of CAR-T cells.
National Blood Clot Alliance collaborates with faith-based organizations on first-of-its-kind church bus tour
AI-driven tools can streamline enrollment and improve efficiency across clinical trials.